1Molecular pathologic characteristics and therapeutic strategy for triple negative breast cancerEXPERT FORUM865-869
2Relationship between ERCC5 promoter polymorphism and chemosensitivity of oxaliplatin-based chemotherapy in patients with advanced colorectal cancerARTICLES870-874
3Effect of transferred c-met antisense gene on vascular endothelial growth factor of human ovarian cancer cell line SKOV3ARTICLES875-878
4Influence of STAT5 siRNA on HeLa cell proliferation and apoptosis and its molecular mechanismARTICLES879-883
5Relationship between expression of βⅢ-tubulin, stathmin and drug resistance to paclitaxel in local advanced non-small cell lung cancerARTICLES884-889
8Experimental research on advanced lung cancer cachexia model with Benefiting qi clearing heat and nourishing yin DecoctionARTICLES900-903
9Prognostic significance of changes in serum levels of CEA during first-line, conventional chemotherapy in patients with advanced non-small cell lung cancerARTICLES904-907
10Prognostic factors of patients with non-small cell lung cancer: A retrospective analysis of 1 560 casesARTICLES908-911
11Survival and efficacy of gefitinib in previously treated patients with advanced lung adenocarcinomaARTICLES912-915
12Trastuzumab in combination with gemcitabine as salvage therapy in metastatic breast cancer with Her2-positiveARTICLES916-918
14Pathological character and clinical analysis of the hepatoid adenocarcinoma of stomach: A report of 11 casesARTICLES923-926
16Whole body hyperthermia combined with chemotherapy in advanced non-small cell lung cancerARTICLES930-932
17Efficacy and safety of DC and DO regimens in the treatment of advanced gastric cancerARTICLES933-935
18A random study of xiaoaiping injection combined with chemotherapy on the treatment of advanced non-small cell lung cancerCLINICAL PRACTICE936-938
19Clinical observation of three dimensional conformal radiotherapy in 28 patients with early esophageal carcinoma diagnosed by endoscopyCLINICAL PRACTICE939-940
